TrialBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2019

Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial.

Chang-Hee Suh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.